Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2°P-TIMI 50 Trial
暂无分享,去创建一个
Marc P. Bonaca | E. Braunwald | D. Morrow | S. Murphy | J. Morais | M. Tendera | B. Scirica | M. Dellborg | D. Angiolillo | M. Cavender | A. Dalby | Ton Oude Ophius
[1] Masafumi Ueno,et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. , 2014, Journal of the American College of Cardiology.
[2] Marc P. Bonaca,et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.
[3] D. Waters,et al. Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.
[4] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[5] D. Angiolillo,et al. Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.
[6] S. Stevens,et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.
[7] Marc P. Bonaca,et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.
[8] E. Antman,et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.
[9] B. Gersh. Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2008 .
[10] Sunil V. Rao,et al. Major bleeding: management and risk reduction in acute coronary syndromes , 2008, Expert Opinion on Pharmacotherapy.
[11] E. Antman,et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. , 2007, American heart journal.
[12] Christopher P Cannon,et al. Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.
[13] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[14] S. Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆ , 2002 .
[15] Deepak L. Bhatt,et al. Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes , 2001, Circulation.
[16] M. Sabatine,et al. Will diabetes save the platelet blockers? , 2001, Circulation.
[17] Deepak L. Bhatt,et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.
[18] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .